Construction of a novel vaccine by conjugating a B-cell epitope of DPP4 to peptide IA2(5)-P2-1 to significantly control type 1 diabetes in NOD mice (Q47370187)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 November 2017

Language	Label	Description	Also known as
English	Construction of a novel vaccine by conjugating a B-cell epitope of DPP4 to peptide IA2(5)-P2-1 to significantly control type 1 diabetes in NOD mice	scientific article published on 20 November 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Construction of a novel vaccine by conjugating a B-cell epitope of DPP4 to peptide IA2(5)-P2-1 to significantly control type 1 diabetes in NOD mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

type-1 diabetes

1 reference

based on heuristic

inferred from title

author name string

Ya Li

1

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Huimin Cao

2

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Yiping Li

3

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Zhixin Li

4

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Xiaomin Wei

5

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Rui Jiao

6

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Peng Cheng

7

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Xiaoran Liu

8

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Yanjie Ma

9

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Yun Xing

10

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Jiali Tang

11

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Min Wang

12

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Taiming Li

13

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

language of work or name

0 references

publication date

20 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

35

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

51

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

7187-7197

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Type 1 diabetes: new perspectives on disease pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Belgian Diabetes Registry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Value of antibodies to islet protein tyrosine phosphatase-like molecule in predicting type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Synthesis and evaluation of pyrazolidine derivatives as dipeptidyl peptidase IV (DP-IV) inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Mapping of novel autoreactive epitopes of the diabetes-associated autoantigen IA-2

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

A new screening method based on yeast-expressed human dipeptidyl peptidase IV and discovery of novel inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Fusion protein His-Hsp65-6IA2P2 prevents type 1 diabetes through nasal immunization in NOD Mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Vildagliptin Ameliorates Oxidative Stress and Pancreatic Beta Cell Destruction in Type 1 Diabetic Rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Vaccination against self to prevent autoimmune disease: the type 1 diabetes model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

HSP65 serves as an immunogenic carrier for a diabetogenic peptide P277 inducing anti-inflammatory immune response in NOD mice by nasal administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Therapeutic vaccine against DPP4 improves glucose metabolism in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Minireview: the glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

A patient with anaphylactoid hypersensitivity to intravenous cyclosporine and subcutaneous phytonadione (vitamin K(1)).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Clinical update on the use of immuno modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Vaccination of non-obese diabetic mice with a fragment of peptide P277 attenuates insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.10.035

7 January 2021

Identifiers

10.1016/J.VACCINE.2017.10.035

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29169891

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47370187&oldid=2154177147"